Andrx CSO resigns
Executive Summary
Andrx Chief Scientific Officer and Pharmaceuticals President Chih-Meng Chen, PhD, resigns. Chen will remain co-chairman of board and will work for Andrx as a consultant. His position as Andrx Pharma president will be temporarily filled by Exec VP and General Counsel Scott Lodin. Andrx is also looking for a CEO. The company announced in April that CEO Alan Cohen will retire (1"The Pink Sheet" April 16, p. 7)
You may also be interested in...
Andrx
Company will seek CEO with experience in brand name drugs to succeed Alan Cohen, who is retiring. Cohen is expected to continue through the transition process
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials